Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML Therapy
Yonina Keschner, Julia Etchin, Mariana Camoesas Silva, Hannah Mager, Hillary Hoyt, Juliana M. Xavier-Ferrucio, Nathan A. Manalo, Amanda L. Halfond, Huan Qiu, Ruijia Wang, Michelle I. Lin, Huanying Gary Ge, Julian Scherer, Tirtha Chakraborty, John R. Lydeard
This study evaluates ADGRE2 as an AML target, showing efficient gene editing in HSPCs to protect against myelotoxicity and developing ADGRE2-specific CAR T cells for therapy.
bioRxiv · Aug 21, 2025 · PreprintCancer Biology